Auxilium Widened Claims For Dupuytren's Contracture Drug Xiaflex, FDA Says
Executive Summary
Auxilium Pharmaceuticals' eagerness to draw attention to its new therapy for Dupuytren's disease, rather than any competitive pressure, has resulted in a speedy FDA "untitled" letter for a Xiaflex promotion